503A vs 503B: what prescribers need to know
The short version
A 503A compounding pharmacy prepares a medication for an identified individual patient against a valid prescription. A 503B outsourcing facility registers with the FDA, produces under CGMP, and may compound in batches without a patient name attached — which is what allows a clinic to keep product on the shelf.
Neither pathway produces an FDA-approved drug. Both are lawful; they answer different clinical questions. The practical test is simple: if you need a preparation tailored to one patient, that is 503A. If you need to administer in-office without waiting for a per-patient fill, that is 503B.
Side-by-side
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| Governing provision | Section 503A of the FD&C Act | Section 503B of the FD&C Act |
| Prescription requirement | Patient-specific prescription required | Patient-specific prescription optional |
| Office stock | Not permitted | Permitted — this is the defining capability |
| Primary oversight | State board of pharmacy | FDA registration and inspection, plus state licensure |
| Manufacturing standard | USP compounding chapters (795, 797, 800) | Current Good Manufacturing Practice (CGMP) |
| Batch size | Small, prescription-driven | Large batches produced ahead of demand |
| Release testing | Per USP requirements for the category | Routine sterility, endotoxin, and potency testing per batch |
| Beyond-use dating | Typically shorter; USP-derived | Typically longer; supported by stability data |
| Adverse event reporting | State-dependent | Mandatory reporting to FDA |
| Typical lead time | Per-prescription; compounded on receipt | Often ships from finished stock |
When 503A is the right pathway
- The patient needs a strength, concentration, or combination that no commercial product offers.
- An excipient, dye, or preservative in the commercial product has to be removed.
- A different dosage form is required — a solution instead of a tablet, a topical instead of an oral.
- The commercial product is unavailable and the preparation is being made for a named patient.
The constraint that surprises practices most often is that a 503A cannot legally supply office stock. Product arrives labelled for one patient and may only be used for that patient, however convenient the alternative would be.
When 503B is the right pathway
- The medication is administered in-office and cannot wait for a per-patient fill.
- Volume is predictable and the practice wants inventory rather than individual orders.
- Longer, stability-supported dating matters for the way the clinic holds stock.
- Institutional policy or a payer requires CGMP production and FDA-registered oversight.
What to verify before you order
Whichever pathway a preparation comes from, the same questions establish whether the source is one you can stand behind:
- Current state licensure in the state where the patient is located, and — for a 503B — active FDA registration.
- Recent inspection history and any outstanding regulatory findings.
- Certificates of analysis available on request, with potency and sterility results for the batch you received.
- The active pharmaceutical ingredient source and whether it is USP grade.
- How beyond-use dates are assigned and what data support them.
- Cold-chain method, validated shipper performance, and what happens when a shipment arrives warm.
- Recall procedure and how quickly you would be notified.
Every fulfillment partner in the VitaRelay network is credentialed against these criteria before it can receive an order, and each item in the catalog carries its compounding category so the pathway is visible at the point of prescribing.
Common questions
What is the difference between a 503A pharmacy and a 503B outsourcing facility?
A 503A pharmacy compounds against a prescription for an identified individual patient. A 503B outsourcing facility registers with the FDA, compounds under CGMP, and may produce batches without patient-specific prescriptions — which is what makes office stock possible.
Can a 503B outsourcing facility dispense to a named patient?
Yes. A 503B may fill patient-specific orders as well as non-patient-specific batches. The distinction is what it is permitted to do, not what it must do.
Are 503B preparations FDA-approved drugs?
No. Neither 503A nor 503B preparations are FDA-approved. A 503B is FDA-registered and inspected and produces under CGMP, but the preparations themselves are not approved products and carry no approved labeling.
Why do beyond-use dates differ between the two?
A 503B routinely performs stability and sterility testing on its batches, which supports longer assigned dating. A 503A assigns dates under the USP compounding chapters based on category, environment, and available supporting data, which is usually shorter.
Regulatory summary for professional education. It is not legal advice, and federal and state requirements change — confirm current obligations with your state board and counsel.